Melinda Magyari, MD, PhD, The Danish Multiple Sclerosis Center, Rigshospitalet, København, Denmark, discusses a study comparing patients with multiple sclerosis (MS) starting a high-efficacy disease-modifying therapy as first-time treatment versus starting medium-efficacy disease-modifying therapies as the first treatment choice. Results suggest that for patients with MS, starting high-efficacy disease-modifying therapies lowers the risk of Expanded Disability Status Scale (EDSS) score worsening and relapses compared to starting medium-efficacy disease-modifying therapies. Lastly, Dr Magyari outlines the importance of personalized medicine in MS. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
Melinda Magyari has served on scientific advisory board for Biogen, Sanofi, Roche, Novartis, Merck, Abbvie, Alexion has received honoraria for lecturing from Biogen, Merck, Novartis, Sanofi, Genzyme, has received research support and support for congress participation from Biogen, Genzyme, Roche, Merck, Novartis.